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Costs were calculated on the actual resources used by
each patient and assigned to the treatment group to which
the patient was randomized. Direct medical resource use
data was costed over six months post transplantation. A
local health economist collected cost information from
published sources and personal interviews with clinicians.
Costs were collected on study drug, concomitant med-
ication, hospitalization, dialysis, and rejection episodes.
To explore the impact of any variability of costs, a one-
way sensitivity analysis was conducted. RESULTS: Six
months after transplantation, patient survival was 99.3%
(Tac) and 98.5% (CyA), p = 0.366; graft survival was
94.6% (Tac) and 91.9% (CyA), p = 0.139. The incidence
of acute graft rejection was 32.5% (Tac) and 51.3%
(CyA), p < 0.0001. Cost-minimization analysis revealed
savings for tacrolimus (per patient) of Euro 583–1874 
for surviving patients, and Euro 781–2305 for patients
with functioning grafts. Tacrolimus was cost-effective for
patients with rejection-free grafts; savings per patient
were Euro 4627–9919. The tacrolimus group consistently
had lower total costs than the cyclosporin group. The cost
advantages for tacrolimus were a result of lower overall
hospitalization costs and lower incidences of dialysis 
and graft rejection. CONCLUSION: A sensitivity analy-
sis regarding the main cost drivers (hospitalization, study
drug, and concomitant medication) generally conﬁrmed
the robustness of this ﬁnding across all three countries.
PRK8
COSTS AND CLINICAL CONSEQUENCES OF
ALFUZOSIN AND DOXAZOZIN IN BENIGN
PROSTATIC HYPERPLASIA IN UKRAINE
Zaliska O, Zchuravchak A
Lviv Medical University, Lviv, Ukraine
OBJECTIVE: Randomized controlled clinical trials have
demonstrated, that alfuzosin (dalfaz R) is comparable to
doxazosin (cardura) in benign prostatic hyperplasia. We
compare the costs and clinical consequences of alfuzosin
vs doxazosin from the perspective of public health care
in Ukraine. Both drugs provide long-lasting relief of
symptoms. METHODS: We compared the rates of PSA
assay, of prostate volume, of while urinary ﬂow (Qmax).
Patients ﬁlled in both the generic IPSS. To calculate the
drug-acquisition costs. RESULTS: A total of 106 patients
(54 alfuzosin, 52 doxazosin) were treated in 6 months.
The mean age of patients was 63.7 years. Relief was seen
as early as one week after the initiation of therapy. We
compared the rates at 1, 3, and 6 months; the prostate
volume decreased by 18% and 19% in the doxazosin and
alfuzosin groups, respectively, while urinary ﬂow (Qmax)
increased by 28 to 29%. The mean percent change in IPSS
was 39.8% (p < 0.05). Overall symptoms improved in
two groups. The direct costs of alfuzosin were 910.0
UAH vs doxazosin 714.1 (1USD = 5.3 UAH) per one
patient. The total cost of 100 patients treated with dox-
azosin were decrease by 27.4% vs alfuzosin. CONCLU-
SIONS: There was no difference in the clinical
consequences of doxazosin vs alfuzosin treatment. Our
study showed that the treatment with doxazosin may
offer economic advantages over alfuzosin, the results 
may provide a basis for creation of formulary system in
Ukraine.
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COST-EFFECTIVENESS OF TAMSULOSIN,
DOXAZOSIN AND TERAZOSIN IN THE
TREATMENT OF BENIGN PROSTATIC
HYPERPLASIA
Ohsfeldt RL1, Kreder KJ1, Klein R2, Chrischilles EC1
1University of Iowa, Iowa City, IA, USA; 2Medical Decision
Modeling, Inc, Indianapolis, IN, USA
OBJECTIVE: To evaluate the cost-effectiveness of 
tamsulosin, doxazosin or terazosin as initial treatments 
for moderate benign prostatic hyperplasia (BPH).
METHODS: A decision analytic model is used to project
the costs and effectiveness of treatment at 6-month inter-
vals over three years following initiation of therapy with
tamsulosin, doxazosin or terazosin. Patients initially
treated with doxazosin or terazosin who discontinue due
to hypotensive events are switched to tamsulosin. Finas-
teride is added in the event of treatment failure not related
to adverse events. Medical treatment failures transition 
to transurethral resection of the prostate (TURP) and, if
needed, a second TURP. Values for treatment failure rates
and clinical event cost parameters are derived from the
literature. Only direct medical costs are included and are
discounted by 3% per year. Effectiveness is measured as
successful medical treatment (without TURP) over three
years. RESULTS: In the reference case, discounted BPH-
related total direct medical costs over 3 years are $3715,
$3756, and $3992 for generic terazosin, generic doxa-
zosin, and tamsulosin, respectively. Estimated medical
treatment success rates at 3 years are 72.41% for tamsu-
losin, 69.62% for terazosin and 69.28% for doxazosin.
The incremental cost for tamsulosin vs. terazosin is $278,
which yields an incremental cost-effectiveness ratio of
$9964 per success. Decision model results are sensitive to
parameter values for treatment efﬁcacy, drug costs, dis-
continuation rates, and dosing frequency. CONCLU-
SION: As an initial medical therapy for moderate BPH,
tamsulosin is more effective than generic terazosin or
doxazosin, with an incremental cost of about $93 per
year or about $7.75 per month. From a payer’s perspec-
tive, with differential generic/brand patient co-pays of
$8/month or more, tamsulosin is cost saving.
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OBJECTIVES: to estimate economic consequences and
patients acceptance of a program proposing a switch
toward self-injection of a recombinant Human erythro-
poïetin (r-HuEPO) NeoRecormon with Reco-Pen® in a
population of adult patients on dialysis. METHODS: A
cost-minimisation study was performed in a societal 
perspective to assess the economic consequences of the
program proposing Reco-Pen®, to facilitate self-injection
in patients requiring a treatment with r-HuEPO. A
random national sample of French patients in mainte-
nance dialysis or in pre-dialysis were selected. A nurse
was dedicated in each centre to educate and assist patients
during the study period. Direct costs of injecting r-
HuEPO before and after the program were estimated
including purchase of the device and erythropoïetin, time
spent by nurses for injection and education of patients or
caregivers. Data were collected on all relevant items ret-
rospectively and prospectively during a 2-month follow
up period. An acceptance study was conducted including
self-evaluation of pain during injection, easiness of use
and satisfaction. RESULTS: One hundred twenty-four
patients in 42 centres were enrolled in Fall 2001. Eighty-
seven percent of patients were in maintenance therapy
and the rest in correction phase. The satisfaction scores
were positive in 80% of patients in terms of improved
autonomy and comfort and 93% declared themselves
ready to go on using the pen. The self-injection rates grew
from 21% to 53%. The switch to Reco-Pen® of 100
patient x year was associated with an economic gain of
€22,449 broken down as following: €18,725 corre-
sponding to the beneﬁt on r-HuEPO purchase cost,
€3,500 corresponding to the costs avoided by reducing
the number of injections performed by ofﬁce-based
nurses, and €224 due to the reduction of total time spent
by nurses in the centres. CONCLUSIONS: The short-
term acceptance of self-injection with Reco-Pen® in a
program proposing the assistance of dedicated nurses is
high and associated with an overall economic beneﬁt.
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THE ECONOMICS OF PHOSPHATE BINDERS IN
RENAL DIALYSIS:A TWO-STAGE STRATEGY FOR
MANAGING HYPERPHOSPHATEMIA
Cangialose CB1,Yeh YC1, Pelham RW2, Nolan CR3,
Qunibi WY3
1Covance Health Economics and Outcomes Services Inc,
Gaithersburg, MD, USA; 2Braintree Laboratories, Brain-
tree, MA, USA; 3University of Texas Health Science
Center at San Antonio, San Antonio, TX, USAOBJEC-
TIVES: Because the outcomes and cost of caring for
patients with ESRD are of major concern, we analyzed
claims data of patients receiving exclusively either
Calcium Acetate (CA) or Sevelamer HCl (SHCl).
METHODS: From the California Medicaid (Medi-Cal)
program we compared 1401 ESRD patients who were
prescribed CA and 192 who were prescribed SHCl during
a 2-year period. RESULTS: For this population, the
median daily dose and cost were 4447mg ($0.55) for CA
and 4030mg for SHCl ($2.88), a signiﬁcant difference by
multivariate regression analysis that controlled for patient
demographics, co-morbidities, hospital admissions, and
time on binder. Not unexpectedly, comorbid conditions
such as COPD, diabetes, heart disease, and hypertension
were signiﬁcantly associated with costs and number of
hospital admissions. However, in patients who had been
prescribed binder for at least 12 months, there was no
statistically signiﬁcant association between choice of
binder, cardiovascular and other co-morbidities, down-
stream medical resource utilization or costs. Moreover,
there was no difference between the binders with regard
to time to ﬁrst hospitalization as well as the number of
hospital admissions. For a hypothetical cohort of 1000
ESRD patients treated over a 2-year period, the use of CA
as a ﬁrst-line agent, switching to SHCl only patients who
become hypercalcemic, would save almost $1.4 million
with no change in patient morbidity. Savings would be
substantially greater if the same approach is followed for
the entire US dialysis population. CONCLUSION: The
choice of phosphate binder does not have a signiﬁcant
impact on the medical costs (except cost of phosphate
binder), or number of hospitalizations, or time to hospi-
talization during follow-up for patients with ESRD.
However, implementing a 2-stage strategy for phosphate
binders has the potential to signiﬁcantly reduce the 
cost of managing hyperphosphatemia in ESRD patients
without having any detrimental effects on this 
population.
URINARY & KIDNEY DISEASES/DISORDERS—
Quality of Life/Preference Based Outcomes
PRK12
COMPARING SENSITIVITY TO CHANGE
BETWEEN I-QOL AND SF-36 IN A POPULATION
WITH URINARY INCONTINENCE
Bushnell DM, Martin M
Health Research Associates, Inc (HRA), Seattle, WA, USA
OBJECTIVE: To report comparisons of the sensitivity 
to change between a condition-speciﬁc quality-of-life
measure (I-QOL, speciﬁc to urinary incontinence) and 
a generic health status measure (SF-36). METHODS:
Incontinent female patients completed the I-QOL and the
SF-36 measures at screening, pre-treatment, and four sub-
sequent follow-up visits during participation in a multi-
center, double-blind, placebo-controlled randomized trial
to assess the efﬁcacy of duloxetine in the treatment of
patients with stress and mixed incontinence. Sensitivity
analyses were conducted using baseline and week 6 data
(or last observation carried forward if participant was an
early dropout). Only responders to stress pad test (25%
decrease), incontinent episodes (25% decrease) and per-
ceived global impression (a little better) were evaluated.
I-QOL scores and SF-36 scores are both transformed onto
a 0 – 100-point scale. RESULTS: For individuals having
a decrease in pad weight of at least 25%, change scores
of the SF-36 ranged from 0 (General Health) to 4 points
(Bodily Pain, Physical Functioning, Role Emotional, and
